OBJECTIVE: Cytochrome P(450) 2C9 (CYP2C9) is a polymorphic enzyme catalysing the metabolism of several important drugs. Losartan has recently been suggested as a selective probe for CYP2C9 metabolic activity. The aim of the study was to determine the activity of CYP2C9, using losartan as a probe drug, in relation to CYP2C9 genotype in healthy Turkish subjects. METHODS: A single oral dose of 25 mg losartan was given to 85 Turkish unrelated subjects. Concentrations of losartan and its carboxylic acid metabolite, E3174, were analysed by means of high-performance liquid chromatography in urine collected for 8 h. The CYP2C9 genotypes were determined in 85 subjects using polymerase chain reaction-based endonuclease digestion methods specific for CYP2C9*2 and *3. Losartan oxidation was also studied in vitro, using human CYP2C8 and CYP2C9 enzymes expressed in yeast. RESULTS: The frequencies of the allelic variants CYP2C9*2 and CYP2C9*3 were 0.100 and 0.088, respectively. The urinary losartan/E3174 ratio was significantly higher in subjects with CYP2C9*1/*3 genotype (median 2.35, n=12) than in subjects with CYP2C9*1/*1 (0.71, n=58) and *1/*2 (0.85, n=10) genotypes ( P<0.05). In contrast to CYP2C9, no E3174 was formed by CYP2C8 in vitro. CONCLUSION: The urinary losartan to E3174 metabolic ratio after a 25-mg losartan dose was found to be a safe and useful phenotyping assay for CYP2C9 activity in vivo. CYP2C9*3 variant allele is a major determinant of the enzyme activity, and it decreases losartan metabolism significantly, while CYP2C9*2 allele has less impact on enzyme function.
OBJECTIVE:Cytochrome P(450) 2C9 (CYP2C9) is a polymorphic enzyme catalysing the metabolism of several important drugs. Losartan has recently been suggested as a selective probe for CYP2C9 metabolic activity. The aim of the study was to determine the activity of CYP2C9, using losartan as a probe drug, in relation to CYP2C9 genotype in healthy Turkish subjects. METHODS: A single oral dose of 25 mg losartan was given to 85 Turkish unrelated subjects. Concentrations of losartan and its carboxylic acid metabolite, E3174, were analysed by means of high-performance liquid chromatography in urine collected for 8 h. The CYP2C9 genotypes were determined in 85 subjects using polymerase chain reaction-based endonuclease digestion methods specific for CYP2C9*2 and *3. Losartan oxidation was also studied in vitro, using humanCYP2C8 and CYP2C9 enzymes expressed in yeast. RESULTS: The frequencies of the allelic variants CYP2C9*2 and CYP2C9*3 were 0.100 and 0.088, respectively. The urinary losartan/E3174 ratio was significantly higher in subjects with CYP2C9*1/*3 genotype (median 2.35, n=12) than in subjects with CYP2C9*1/*1 (0.71, n=58) and *1/*2 (0.85, n=10) genotypes ( P<0.05). In contrast to CYP2C9, no E3174 was formed by CYP2C8 in vitro. CONCLUSION: The urinary losartan to E3174 metabolic ratio after a 25-mg losartan dose was found to be a safe and useful phenotyping assay for CYP2C9 activity in vivo. CYP2C9*3 variant allele is a major determinant of the enzyme activity, and it decreases losartan metabolism significantly, while CYP2C9*2 allele has less impact on enzyme function.
Authors: Umit Yasar; Stefan Lundgren; Erik Eliasson; Anna Bennet; Björn Wiman; Ulf de Faire; Anders Rane Journal: Biochem Biophys Res Commun Date: 2002-11-22 Impact factor: 3.575
Authors: Craig R Lee; John A Pieper; Reginald F Frye; Alan L Hinderliter; Joyce A Blaisdell; Joyce A Goldstein Journal: Eur J Clin Pharmacol Date: 2003-02-26 Impact factor: 2.953
Authors: U Yasar; E Eliasson; C Forslund-Bergengren; G Tybring; M Gadd; F Sjöqvist; M L Dahl Journal: Eur J Clin Pharmacol Date: 2001-12 Impact factor: 2.953
Authors: Magnus Christensen; Katarina Andersson; Per Dalén; Rajaa A Mirghani; Gary J Muirhead; Anna Nordmark; Gunnel Tybring; Anneli Wahlberg; Umit Yaşar; Leif Bertilsson Journal: Clin Pharmacol Ther Date: 2003-06 Impact factor: 6.875
Authors: Ahmet Kocael; Allison Pınar Eronat; Mete Bora Tüzüner; Ahmet Ekmekçi; Ahmet Lütfullah Orhan; İbrahim İkizceli; Hülya Yılmaz-Aydoğan; Oğuz Öztürk Journal: Mol Biol Rep Date: 2019-02-02 Impact factor: 2.316
Authors: Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke Journal: Clin Pharmacokinet Date: 2014-03 Impact factor: 6.447